



The seeds for a Canadian organization of CLL patients were planted in 2002 at an education meeting organized by Ontario CLL patients. It was formalized under the name of the CLL Patient Advocacy Group in 2007. In November 2020, it became CLL Canada and continues as a volunteer driven organization of CLL patients and persons with an interest in CLL.

Our Mission Statement

Advocate and provide education to improve access to health care that will extend the lives of Canadians affected by Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Guiding Principles

- Healthcare for CLL/SLL must be equally accessible to all in Canada.
- Informed patients make better decisions. Knowledge is essential for CLL/SLL patients to make the best health care choices.
- Comprehensive diagnosis and individualized health care are the keys to effective management of this as yet incurable blood cancer.
- Targeted therapies lead to more effective individualized health care and improve patient outcomes in terms of quality and extension of life.
- Translational research (from basic/lab research to clinical patient interventions) is essential for the development new CLL/SLL treatments. Clinical trials based on this research in CLL/SLL, significantly improve patient outcomes.
- **CLL Canada does not promote individual pharmaceutical companies or their products.**
- **CLL Canada operates with transparency; we undertake to be open, honest and accountable in our relationships with everyone we work with and with each other.**

Objectives

1. Provide a patient voice in the drug approval process.
2. Contribute to and/or support patient education.
3. Disseminate information, including research, to patients and caregivers.
4. Promote or advocate for research in the field of CLL/SLL.
5. Partner with other organizations to meet our objectives.